A randomized phase i evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy

Clinical Pharmacology in Drug Development

Volumn 2, Issue 1, 2013, Pages 53-66

  Braman, Virginia ^a   Graham, Philip ^a   Cheng, Changfu ^a   Turnquist, David ^a   Harnett, Mark ^a   Sabounjian, LuAnn ^a   Shipley, James ^a  

^a Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

Chronic kidney disease; Deuterium; Diabetic nephropathy; Pharmacokinetics

Indexed keywords

[1 [5 HYDROXYHEXYL] 3,7 DIMETHYLXANTHINE]; C 21256; CTP 499; D M 2; D M 3; D M 4; DEUTERIUM; DRUG METABOLITE; M 5; METHYLXANTHINE DERIVATIVE; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG;

ADULT; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE FORMULATION; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SINGLE DRUG DOSE; VOMITING;

EID: 84892489056     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.3     Document Type: Article

References (16)

1. United States Renal Data System, USRDS 2009 Annual Data Report; Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2009. 2009 Annual Report. http://www.usrds.org/adr.htm Accessed June 3, 2010.
2. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12-S154.
3. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
4. American Diabetes Association. Standards of medical care -2010. Diabetes Care. 2010;33:S11-S61.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
6. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97.
7. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433-442.
8. Crouch SPM, Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immunol. 1992;60: 11, 4504-4509.
9. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54:205-226.
10. Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail. 2010;32:172-178.
11. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail. 2003;25:465-470.
12. Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3-10.
13. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464-474.
14. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53:606-616.
15. Parasrampuria, DA, Braman V, Cheng C, et al. First Human Exposure Suggests aUniqueMetabolic Profile with Multiple Active Species for CTP-499, a Novel Agent for Treatment of Chronic Kidney Disease. Poster session presented at CKD, AKI,DM,Clinical:Clinical Trials,HealthServicesResearch, and Ethics, American Society of Nephrology Kidney Week 2011, November 8-13, 2011. Philadelphia, PA.
16. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-1283.